| Literature DB >> 35224019 |
Abstract
Crohn's disease may cause a life-long disease burden in many aspects due to its progressive nature. A large proportion of refractory patients have been benefiting from scheduled maintenance anti-TNF treatment; therefore, strategy to stop anti-TNF agents in Crohn's disease is not widely conducted. There have been observational studies demonstrating that approximately half of the patients relapse within a year after discontinuation. Several factors have been suggested as potential predictors for relapse; however, a consensus has not been reached so far. Although most relapse can be rescued by the re-treatment with the same anti-TNF agent, a proportion of patients may result in progressive bowel damage and the need for surgery. Therefore, an attempt to stop anti-TNF is not recommended without careful discussion, even if they are in long-term remission.Entities:
Keywords: Adalimumab; Crohn's disease; De-escalation; Inflammatory bowel disease; Infliximab
Year: 2021 PMID: 35224019 PMCID: PMC8820156 DOI: 10.1159/000517961
Source DB: PubMed Journal: Inflamm Intest Dis ISSN: 2296-9365